Recommended

GSK appoints new CEO
New webinar | Addressing the time-to-result challenge posed by short shelf-life radiopharmaceuticals, register today
Genmab acquires biotech Merus for $8bn
US FDA licensing first for IL-23 inhibitor to treat paediatric psoriasis
Teva makes progress on API business divestment
Takeda to move away from cell therapy
news

AstraZeneca cancels £450m Liverpool vaccine facility expansion

0
SHARES

Posted: 10 February 2025 | | No comments yet

Under growing global competition, this development highlights potential challenges for the UK to uphold large-scale pharmaceutical investments.

AstraZeneca vaccine facility

Credit: Radowitz / Shutterstock.com

AstraZeneca has scrapped its planned £450 million expansion of a vaccine manufacturing facility in Liverpool, UK, citing economic factors and reduced government funding.

 

ACCESS your FREE COPY

 


This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.

Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.

What you’ll discover:

  • Key trends shaping the pharmaceutical formulation sector
  • Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
  • Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
  • And more!

Don’t miss your chance to access this exclusive report ! Access now – it’s free

The decision follows changes in government support, with promised funding from the previous administration significantly reduced under the new cost-saving measures implemented by the current Labour government.

Government support and financial challenges

Initially, the UK government pledged £90 million to help fund the project. However, revised budget allocations led to a reduction in financial backing, making the investment unfeasible for AstraZeneca.

“We couldn’t make the business case work and couldn’t make the investment economically viable. We needed the same level of support to make this economically viable. It wasn’t possible for the Government to justify it, which we totally understand, and we said we couldn’t justify it either. We were all very disappointed, but that’s business life,” Pascal Soriot, CEO of AstraZeneca, told The Guardian.

Cancellation of AstraZeneca’s Liverpool vaccine manufacturing facility

Impact on UK’s pharmaceutical sector

As global pharmaceutical companies seek stability and financial incentives, responsibility lies with the government to ensure that the UK remains a viable destination for research, development, and manufacturing investments”

The cancellation raises concerns about the UK’s competitiveness in pharmaceutical manufacturing. With increasing global competition, including incentives from countries such as Singapore and the US, AstraZeneca’s move signals potential challenges for the UK’s ability to retain large-scale pharmaceutical investments.

AstraZeneca remains committed to its UK operations but continues to assess opportunities in regions that offer more favourable financial conditions and regulatory support.

Industry experts warn that this development could have long-term implications for the UK’s life sciences sector. As global pharmaceutical companies seek stability and financial incentives, responsibility lies with the government to ensure that the UK remains a viable destination for research, development, and manufacturing investments.

International investment

Despite this setback in the pharmaceutical firm’s UK operations, a new investment announced the last month will focus on strengthening its presence in Canada, supporting the company’s goal of bringing 20 novel medicines to patients worldwide by the end of the decade.

Share via
Share via